Quanterix Q2 revenue drops 29% to $24.5M; net loss widens to $30M; guides FY25 revenue $130-135M

Quanterix Corp

2025-Q2 EPS reported -$1.30 vs consensus -$0.37 ▼ miss (-254.0%)

GAAP net loss $30.0M vs $7.4M in Q2 2024; GAAP gross margin 46.2% vs 64.7%.
Revenue $24.5M down 29% YoY; Alzheimer's Diagnostics revenue more than tripled.
Closed Akoya acquisition in early July; $64M of $85M cost reduction target achieved.
FY 2025 revenue guidance $130-135M (incl. ~2 quarters Akoya); pro forma $165-170M.
Expects cash flow breakeven in 2026; exiting 2025 with ~$120M cash.

item 2.02 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Quanterix Corp: Adopted amended and restated bylaws to implement majority voting standard for uncontested director elections, replacing plurality standard (effective 2025-08-05).

Change: bylaw amendment
Effective: 2025-08-05

Exact text from the filing

On and effective as of August 5, 2025, the Board of Directors (the “Board”) of Quanterix approved and adopted amended and restated bylaws (the “Restated Bylaws”) to implement a majority voting standard for uncontested director elections (in place of a prior plurality standard).

View on SEC.gov

99 governance changes filed in the last 30 days. Browse all governance changes →

Quanterix Corp filing history →

Source: SEC EDGAR

accession 0001503274-25-000089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.